Text Size
127 studies found for:    myeloma and velcade | Open Studies

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: TH-302;   Drug: TH-302 and bortezomib
2 Recruiting Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Procedure: Autologous Stem Cell Transplant;   Drug: Fludarabine
3 Unknown † VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)
Condition: Multiple Myeloma
Intervention: Drug: bortezomib
4 Recruiting Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Conditions: Cancer;   Myeloma;   Multiple Myeloma
Intervention: Drug: Bortezomib
5 Recruiting Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: total marrow irradiation;   Drug: tacrolimus;   Drug: sirolimus;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
6 Recruiting Filgrastim in Treating Patients With Bortezomib- or Carfilzomib-Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: G-CSF and Bortezomib or Carfilzomib
7 Recruiting Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Conditions: Multiple Myeloma;   Auto Stem Cell Transplant
Intervention: Drug: Bortezomib
8 Recruiting Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone;   Drug: Velcade plus dexamethasone
9 Recruiting Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide, cyclophosphamide, dexamethasone;   Drug: thalidomide, cyclophosphamide, dexamethasone;   Drug: bortezomib, cyclophosphamide, dexamethasone;   Drug: lenalidomide maintenance;   Drug: lenalidomide plus vorinostat maintenance
10 Recruiting A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ganetespib;   Drug: Bortezomib;   Drug: Dexamethasone
11 Recruiting Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Plerixafor (AMD3100);   Drug: bortezomib
12 Recruiting High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Other: pharmacological study;   Drug: tacrolimus;   Drug: sirolimus;   Biological: anti-thymocyte globulin;   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: bortezomib;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
13 Recruiting Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: GSK2110183;   Drug: Bortezomib;   Drug: Dexamethasone
14 Recruiting Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Refractory Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: bortezomib;   Drug: dexamethasone;   Other: laboratory biomarker analysis;   Other: gene expression analysis
15 Recruiting Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients
Condition: Multiple Myeloma
Intervention: Drug: velcade
16 Recruiting A Study to Evaluate the Use of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Cyclophosphamide;   Drug: Velcade;   Drug: Chloroquine
17 Recruiting Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
18 Not yet recruiting Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
Condition: Multiple Myeloma
Intervention: Drug: Velcade
19 Recruiting Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
20 Recruiting Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: cyclophosphamide;   Drug: lenalidomide;   Other: laboratory biomarker analysis;   Drug: dexamethasone;   Procedure: quality-of-life assessment
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years